Additionally, PTC analyzed long-term open-label data from an earlier study of vatiquinone in adults with FA. Following 24-months of treatment with vatiquinone, subjects had a 4.8-point benefit on the ...

Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Deficiencies is magnesium, vitamin D, or certain B vitamins may contribute to muscle cramps. Here’s what you need to know and ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

Rashi Narang, Founder and Creative Director at Heads Up For Tails, shared that this distress can be caused by chronic ...

Bill Nye, the beloved 'Science Guy' says many of his family members suffer from Ataxia, a rare neurological disorder that ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.

U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria. Larimar will present three posters ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments ...

This can cause cells to replicate rapidly and inactivate proteins that suppress tumors, said Denise Galloway, scientific director of the Pathogen-Associated Malignancies Integrated Research Center ...